Skip to main content Back to Top
Advertisement

2/28/2024

Etoposide Solution for Injection

Products Affected - Description

    • Etoposide solution, Accord, 20 mg/mL, 25 mL multiple dose vial, 1 count, NDC 16729-0114-08
    • Etoposide solution, Accord, 20 mg/mL, 5 mL multiple dose vial, 1 count, NDC 16729-0114-31
    • Etoposide solution, Accord, 20 mg/mL, 50 mL multiple dose vial, 1 count, NDC 16729-0114-11
    • Etoposide solution, Fresenius Kabi, 20 mg/mL, 25 mL multiple dose vial, 1 count, NDC 63323-0104-25
    • Etoposide solution, Hikma, 20 mg/mL, 5 mL multiple dose vial, 1 count, NDC 00143-9510-01
    • Etoposide solution, Hikma, 20 mg/mL, 50 mL multiple dose vial, 1 count, NDC 00143-9512-01

Reason for the Shortage

    • Accord has etoposide injection on shortage due to manufacturing delays.
    • Fresenius Kabi did not provide a reason for the shortage.
    • Hikma did not provide a reason for the shortage.
    • Teva stopped marketing etoposide injection in 2022.

Available Products

    • Etoposide solution, Fresenius Kabi, 20 mg/mL, 5 mL multiple dose vial, 10 count, NDC 63323-0104-05
    • Etoposide solution, Fresenius Kabi, 20 mg/mL, 50 mL multiple dose vial, 1 count, NDC 63323-0104-50
    • Etoposide solution, Hikma, 20 mg/mL, 25 mL multiple dose vial, 1 count, NDC 00143-9511-01

Estimated Resupply Dates

    • Accord has etoposide 20 mg/mL 5 mL, 25 mL, and 50 mL vials on back order and the company estimates a limited release in early-March 2024.
    • Fresenius Kabi has etoposide 20 mg/mL 25 mL vials on back order and the company estimates a release date of early-March 2024. The 50 mL vials are on back order and the company cannot estimate a release date.
    • Hikma has etoposide 20 mg/mL 5 mL, 25 mL, and 50 mL vials on back order and the company estimates a release date of late-May 2024 for the 5 mL and 50 mL vials and late-August 2024 for the 25 mL vials.

Updated

Updated February 28, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 31, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.